Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Chipotle

Eli Lilly

ONEOK

Ross Stores

CNBC's Jim Cramer is looking to 2011 for investing guidance during the ongoing debt ceiling uncertainty.

Jim Cramer expects defensive stocks to be resilient as debt ceiling talks drag on

Two new medicines are going to compete for the Alzheimer's therapy market. Eli Lilly's candidate appears to be more effective, but it isn't approved yet.

These 2 Pharma Stocks Might Face Off Soon -- but They Could Both Win

Biogen has been struggling in recent years, but a couple of new products could help bolster its top line. The stock trades at a discount, which may be an opportunity, especially given the potential for Leqembi.

3 Reasons to Buy Biogen Stock (and 1 to Sell)

The shares of Biogen Inc (NASDAQ:BIIB) are enjoying tailwinds from positive news surrounding sector peer Eli Lilly's (LLY) Alzheimer's drug  donanemab.

Biogen Stock Hits Fresh High on Eli Lilly Buzz

Eli Lilly stock popped Wednesday after the company said its experimental Alzheimer's treatment significantly slowed cognitive decline. The post Eli Lilly Surges After Alzheimer's Treatment Succeeds; Biogen Also Rises appeared first on Investor's Business Daily.

Eli Lilly Surges After Alzheimer's Treatment Succeeds; Biogen Also Rises

Biogen Inc. BIIB has priced its recently approved ALS treatment Qalsody at $14,230 per vial, a spokesperson confirmed to MarketWatch on Tuesday. The drug, also known as tofersen, was granted accelerated approval by the U.S. Food and Drug Administration last week.

Biogen prices new ALS treatment at $14,230 per vial

Quest Diagnostics

Patients could face wait times ranging from 18 months to four years or more to get diagnosed and then treated for Alzheimer's disease.

Alzheimer's patients may wait years to get treated with new drugs, putting them at risk of more severe disease

Buy Biogen For Runups To Imminent Regulatory Decisions.

Buy Biogen For Runups To Imminent Regulatory Decisions

Altimmune

Axsome Therapeutics

The biotech sector is up 4.76% so far in 2023. This continues the nice run that biotech stocks had in 2022.

The 3 Most Promising Biotech Innovations in 2023 and the Stocks to Buy

CAMBRIDGE, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today that the U.S. Food and Drug Administration (FDA) has approved QALSODY™ (tofersen) 100 mg/15mL injection for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. This indication is approved under accelerated approval based on reduction in plasma neurofilament light chain (NfL) observed in patients treated with QALSODY. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s).1 The ongoing Phase 3 ATLAS study of tofersen in people with presymptomatic SOD1-ALS will serve as the confirmatory trial.1

FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS

The U.S. Food and Drug Administration said Tuesday it has granted accelerated approval to Biogen Inc.'s BIIB torferson, a treatment for a rare form of amyotrophic lateral sclerosis, or ALS. The accelerated approval program is used to OK drugs for serious conditions with an unmet medical need, where a drug is shown to have an effect on an endpoint that is reasonably likely to predict a clinical benefit to patients.

FDA grants accelerated approval to Biogen's treatment for rare form of ALS

Biogen CEO Christopher Viehbacher said during an earnings call that Eli Lilly needs to consider maintenance doses its Alzheimer's treatment donanemab.

Biogen isn't concerned about competing with Eli Lilly in the Alzheimer's drug space, CEO says

The FDA's approval requires Biogen to further study its ALS drug tofersen to further verify its clinical benefits.

FDA grants accelerated approval for Biogen ALS drug that treats rare form of the disease

Biogen (BIIB) beats first-quarter estimates for earnings and sales. It maintains its 2023 guidance.

Biogen (BIIB) Beats on Q1 Earnings, Ends Some Research Programs

Biogen Inc. (BIIB) Q1 2023 Earnings Call Transcript.

Biogen Inc. (BIIB) Q1 2023 Earnings Call Transcript

The headline numbers for Biogen Inc. (BIIB) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Biogen Inc. (BIIB) Reports Q1 Earnings: What Key Metrics Have to Say

Biogen Inc. (BIIB) came out with quarterly earnings of $3.40 per share, beating the Zacks Consensus Estimate of $3.25 per share. This compares to earnings of $3.62 per share a year ago.

Biogen Inc. (BIIB) Beats Q1 Earnings and Revenue Estimates

Biogen stock fell early Tuesday as the company reiterated its outlook for declining sales despite its new Alzheimer's treatment. The post Alzheimer's Drugs Still Aren't Biogen's Saving Grace — But The Company Is Hopeful appeared first on Investor's Business Daily.

Alzheimer's Drugs Still Aren't Biogen's Saving Grace — But The Company Is Hopeful

Biogen Inc. BIIB said Tuesday it had net income of $387.9 million, or $2.67 a share, for the first quarter, up from $303.8 million, or $2.06 a share, in the year-earlier period. Adjusted per-share earnings came to $3.40, ahead of the $3.28 FactSet consensus.

Biogen tops estimates as revenue slides 3% from a year ago

Vertex Pharmaceuticals

Biogen and Vertex are both waiting on big regulatory decisions for potential products. The companies each bring in billions of dollars in revenue every year.

Better Big Biotech Buy: Biogen vs. Vertex

Biogen's (BIIB) sales in the first quarter are likely to have been hurt by lower sales of multiple sclerosis drugs, while sales of Spinraza are likely to have improved.

Biogen (BIIB) to Report Q1 Earnings: Here's What to Expect

Biogen Inc. (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Biogen Inc. (BIIB) Q1 Earnings Expected to Decline

Biogen Inc (NASDAQ:BIIB) is buzzing today, after Piper Sandler and Wedbush praised the drugmaker ahead of the company's first-quarter earnings report -- due out before the market's open on Tuesday, April 25.

Bulls Blast Biotech Stock Before Earnings

Alzheimer's patients who take Leqembi retain the benefits of the treatment even when they stop taking it, new research by Eisai and Biogen shows.

Alzheimer's patients retain the benefits of Leqembi even when they stop the drug, Eisai says

Ionis Pharma

Ionis and Biogen have been partnering on antisense drug development for a decade. The two companies won approval for $1.8bn (in 2022) Spinraza, indicated for Spinal Muscular Atrophy.

News for Biogen Stock (BIIB)